Skip to content

Association between tumor volume reduction and treatment outcomes in nasopharyngeal carcinoma treated with PCE-based induction chemotherapy and concurrent chemoradiotherapy.

Oct 2026 · International Journal of Clinical Oncology · 0 citations · 20 references
Medicine

TL;DR

VRR was associated with PFS, suggesting that tumor shrinkage following IC-PCE may serve as a prognostic marker in patients with locoregional advanced nasopharyngeal carcinoma.

View source

Similar papers

Open access Sep 2026

Individual and Cumulative Impacts of Diagnosis-to-Treatment Interval and Radiotherapy Interval on Survival in Nasopharyngeal Cancer.

OBJECTIVE To evaluate the impact of diagnosis-to-treatment interval (DTI) and radiotherapy interval (RTI) on overall survival (OS) in locally advanced nasopharyngeal carcinoma (LA-NPC) treated with concurrent chemoradiotherapy (CCRT). STUDY DESIGN Retrospective database study. SETTINGS Single tertiary academic cent...

E. Topkan, E. Somay, S. Başçıl et al. · 0 citations
Open access Oct 2026

Metastasis-directed therapy in addition to definitive locoregional radiotherapy for De novo metastatic nasopharyngeal carcinoma: a retrospective cohort study

Background De novo metastatic nasopharyngeal carcinoma (mNPC) carries a poor prognosis with systemic therapy alone. Locoregional radiotherapy (LRRT) improves survival in chemotherapy-responsive patients, but the incremental role of metastasis-directed therapy (MDT) remains undefined. Methods This retrospective cohort i...

S. Ghosh-Laskar, Anuj Kumar, R. Malhotra et al. · 0 citations
Open access Oct 2026

Efficacy of immediate radiotherapy versus salvage radiotherapy in patients with de novo metastatic nasopharyngeal carcinoma responsive to chemoimmunotherapy

Background Chemoimmunotherapy has become the standard first-line treatment for de novo metastatic nasopharyngeal carcinoma (dmNPC). However, the role and optimal timing of locoregional radiotherapy in dmNPC in the chemoimmunotherapy era remain unclear. This study aims to evaluate whether salvage locoregional radiothera...

Qi-Tong Zhang, Jia-Rui He, H.-B. Guo et al. · 0 citations
Open access Sep 2026

Concomitant chemoradiotherapy for head and neck squamous cell carcinoma: Real-world treatment delivery, toxicity, and survival in Bosnia and Herzegovina.

Real-world evidence on concomitant chemoradiotherapy (CCRT) for head and neck squamous cell carcinoma (HNSCC) in Bosnia and Herzegovina remains limited. We aimed to characterize treatment delivery, toxicity, and survival and identify modifiable barriers to optimal care. This retrospective single-institution cohort stud...

Gordana Berić Jozić, M. Mabić, Monika Glibić et al. · 0 citations
Open access Oct 2026

Real-world outcomes of definitive radiotherapy for muscle-invasive bladder cancer: A single-center experience.

698 Background: Bladder-preserving chemoradiotherapy is an established treatment option for selected patients with muscle-invasive bladder cancer (MIBC). This study evaluated survival outcomes, toxicities, and prognostic factors in patients treated with definitive radiotherapy with or without concurrent chemoth...

Alshaymaa Abdelghaffar · 0 citations

We use cookies to run the site and, with your consent, for analytics and to show ads. See our Cookie Policy.